Monday, October 15, 2018
 
 
Company News: Page (1) of 1 - 01/12/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Sci-Engi-Medco Solutions Inc. Awarded SBIR Phase 1 NCI Contract to Study Its Lead Molecules in Preclinical Model of Triple Negative Breast Cancer
 
(January 12, 2018)
This article is no longer available,but here are some related topics.


Page: 1


Related Keywords: Inc.,Medicine,medical technologists,Cancer,Surgery,Medication,Womens Health,Science,Lifestyle,Medical,Biology,Stem Cell,Cancer,Business,Science,
Related Sites: DMN Newswire ,   CEN - Consumer Electronics Net ,   VideoBasedTutorials ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Lee Health Selects GeBBS iCode Assurance SaaS Solution for HIM Auditing Workflow and Analytics
  • Global $6.87 Billion Contrast Agents/Media Market to 2025
  • Contrast Agents/Media Market, 2025
  • Global mHealth market is projected to attain a size of $132.2 billion by 2023
  • Biosurgery Market Analysis | Rising Investments in Healthcare and Expansions by Most Eminent Players Globally | Forecast 2023

    Cancer
  • Roche's Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
  • InSight Telepsychiatry Presents First Annual Partner Awards
  • Internet Brands' WebMD Acquires prIME Oncology
  • Global Next Generation Sequencing Market: Whole Genome Sequencing is Growing at the Fastest CAGR | Emerging Trends & Strategy Analysis, by Key Players; Illumina, Inc., Qiagen, Agilent Technologies, Ge
  • Connected Health Conference 2018 Keynote Series: FCC Chairman Ajit Pai, Champion Of Rural Broadband And Telehealth
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines